A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Status:
RECRUITING
Trial end date:
2029-07-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma (MM).